Although several SFK inhibitors have been developed, clinical trials in CRC have produced disappointing results probably because of the absence of selection of patients with SRC-dependent tumours and/or the drug’s inability to efficiently target SRC signalling [24,31,32,33]. This evidence concerns the gene SRC and colorectal carcinoma.